ABSTRACT
INTRODUCTION
Differentiated thyroid cancer (DTC) make up the vast majority of thyroid cancers. The initial diagnosis of thyroid carcinoma and the distinction between benign and neoplastic disease can be challenging. Radioiodinerefractory metastatic DTC also presents a therapeutic dilemma. Novel targeted agents for advanced radioiodinerefractory metastatic thyroid cancer, such as tyrosine kinase inhibitors (TKIs), are being increasingly used with clinical success, broadening current available therapeutic options.
CASE REPORT
A 61-year-old Cambodian woman presented in 2008 to our institution with pelvic pain secondary to metastatic follicular thyroid carcinoma. She had undergone a left hemithyroidectomy 20 years prior for a benign nodule and subsequently developed a right-sided nodule 11 years later measuring 3.5 × 3.5 × 2.5 cm. A fine needle aspirate (FNA) was suggestive of papillary carcinoma and she underwent completion thyroidectomy. However, postoperative histology revealed Hurthle cell adenoma and thus, she received no adjuvant therapy.
Subsequent computed tomography (CT) scan showed pelvic and skull metastases ( Figs 1A and B) . Sacroiliac biopsy confirmed metastatic follicular thyroid carcinoma (positive immune staining for thyroglobulin, cytokeratin-7, and thyroid transcription factor-1). Initial management included therapeutic radioactive iodine (RAI, 198 mCi I-131), external beam radiotherapy (EBRT) to pelvis and skull, and eight cycles of doxorubicin with symptomatic improvement.
Three years later, she developed further skull and skeletal metastases in her ribs, T4, and L1 vertebral bodies. She underwent excision of the skull lesion and received two further doses of RAI (cumulative dose 578 mCi I-131). Post-RAI, whole-body scan (WBS) revealed disease progression consistent with RAI-refractory disease, including new uptake in multiple thoracolumbar vertebral bodies, pelvis, and bilateral femur (Fig. 2) . Her disease was Fluorodeoxyglucose (FDG-avid). In the setting of progressive, RAI-refractory disease and good performance status, pazopanib was commenced. She achieved initial biochemical response with declining wjoes thyroglobulin levels; however, treatment was complicated by myelosuppression and hypertension necessitating dose reduction. Pazopanib was ceased 17 months later due to progressive disease.
She has since experienced rapid progression with innumerable skeletal metastases within the manubrium and sternum; pathological fractures of the sternum, bilateral humeri, and pubic rami; and cranial nerve impingement secondary to a skull base lesion. She has now received further EBRT as well as orthopedic fixation to the humeri. She subsequently also developed T10 spinal cord compression that was managed with high dose of dexamethasone.
Gene mutation analysis of tumor tissue showed wildtype NRAS and BRAF. Further, 2nd line systemic therapy was considered given failure of 1st line TKI therapy; however, it was felt to be inappropriate due to her rapidly declining functional status. Her thyroglobulin levels continue to rise (Graph 1). Currently, she is maintained on suppressive thyroxine, alendronate, calcium, vitamin D, and opiate analgesia.
DISCUSSION
Hurthle cell neoplasms are considered a variant of thyroid follicular cell carcinoma and are predominantly comprised 3 The disparate findings between the initial FNA and postoperative histology in this case were unusual; however, retrospective analysis of both samples has confirmed the original cytological and subsequent histological diagnoses. Given the incongruence, measurement of a serum thyroglobulin level and long-term surveillance may have been useful retrospectively given the suggestion of carcinoma on initial cytology. Radioactive iodine-refractory (RAI) metastatic DTC presents a significant therapeutic challenge. While most patients with DTC have an excellent prognosis, 10 to 15% of patients will either present with or develop metastatic disease 4 and two-thirds will progress to RAI-refractory disease. 5 Historically, 10-year median survival rate is only 10% for RAI-refractory metastatic DTC due to poor response to cytotoxic chemotherapy, such as doxorubicin. 4 However, improved understanding of the molecular pathways promoting growth and tumorigenesis in metastatic DTC has led to the development of multi-targeted TKIs, which offer a novel treatment option for patients with metastatic, rapidly progressive and/or symptomatic disease not amenable to local control. In this case, pazopanib was the chosen TKI following results of a phase II trial published that year. 6 was not reached at the time of data cutoff for each agent and any difference compared to placebo may be affected by significant crossover. However, the potential adverse effects of TKIs are substantial, including myelosuppression, severe cutaneous complications including hand-foot syndrome, hypertension, and secondary malignancies including squamous cell carcinoma. Adverse effects may necessitate dose reduction or treatment cessation. Accordingly, their use should be limited to patients with good performance status and those at significant risk of morbidity or mortality due to progressive disease. To date, there is little evidence and no prospective studies investigating the efficacy of salvage therapy following 1st line TKI failure. Given the similarity of drug targets, cross-resistance and reduction or loss of efficacy may occur with sequential TKI therapy. However, retrospective studies have suggested that other TKIs are effective salvage therapies after 1st line TKI failure. 9 Partial response occurred in 41% and stable disease in 59% of patients receiving salvage therapy with another TKI after sorafenib failure. 9 The median overall survival and PFS
were also significantly longer. 9 Recent clinical trials have also assessed a novel application for TKIs in restoring radioiodine uptake and responsiveness in RAI-refractory metastatic DTC. 5 The refractory disease is thought to occur through loss of sodium-iodide symporter expression due to aberrant activation of the mitogen-activated protein kinase (MAPK) pathway and/or Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-protein kinase B (AKT)-mammalian target of rapamycin (mTOR) pathway. 5 Selumetinib is a TKI that inhibits MEK1/2, a component of the MAPK pathway. A phase II trial demonstrated the ability of selumetinib to resensitize patients with RAI-refractory metastatic DTC to radioiodine therapy. 10 Increased iodine uptake was observed in 60% of patients, with a subsequent 40% displaying sufficient uptake to receive a further dose of therapeutic RAI. During follow-up, there were partial responses in five patients and stable disease in three. Tumor genotype affected response, with the greatest efficacy in patients with NRAS-mutant tumors and least efficacy in those with BRAF-positive tumors. It was well tolerated and may have a favorable cost-benefit analysis as therapy is needed only for 4 weeks per cycle. Our patient experienced significant morbidity due to a high burden of skeletal metastatic disease, notoriously resistant to treatment. 11 
CONCLUSION
In summary, this complex case illustrates the challenges in managing radioiodine-refractory metastatic DTC with skeletal dominant metastases. The advent of TKIs as emerging frontline and salvage therapy is a novel addition to the future of thyroid cancer. Future studies expanding the role of sequential and redifferentiation therapy for advanced disease and strategies to reduce SREs are needed.
CLINICAL SIGNIFICANCE
This case highlights the challenges in the diagnosis of thyroid cancer, in particular the importance of accurate histological diagnosis and long-term clinical surveillance of apparently benign thyroid oncocytic tumors in those at high risk. We also review the management of radioiodine-refractory metastatic DTC focusing on the role of the novel TKIs.
